Blog
Product strategy, conversion systems, and telehealth operations for teams building modern care journeys.
Peptide Clinic Software: What a Compliant Program Needs After the October Policy
Peptide clinic software has a new spec since HHS's October 28 policy on six compounded peptides: one active ingredient per product, routes locked per peptide, adverse events reported to MedWatch and the states, a fixed label statement, and only cleared syringes in the box. Most of that is the pharmacy's job, but the software decides whether your catalog, intake and refills ever ask the pharmacy for something it cannot make. Here are the seven requirements, the questions to ask a vendor, and how an EHR build, an all-in-one platform and a pharmacy storefront compare.
HHS Will Not Enforce Against Six Compounded Peptides: A Launch Checklist Built on the 10 Conditions
On October 28, 2026, HHS said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon, if ten conditions are met. The notice calls the policy a draft and an interim policy, law firms disagree on whether it is operative today, and FDA's own reviewers recommended against all six. Here is each condition mapped to what the brand, the prescriber and the pharmacy have to do, what the policy does not allow, and what LegitScript changed on November 2.
How to Start a Peptide Clinic in 2026: What Is Legal Today and What Waits on the FDA
Peptides are the most-searched new clinic category of 2026 and the most misunderstood. FDA moved twelve peptides off its Category 2 list in April, an advisory committee reviewed seven of them in July, Hims says it has six ready to launch, and as of September none of that had made BPC-157 legal to prescribe (HHS's October 28 enforcement policy has since changed that, with conditions). Here is the legal map as of September 2026, the peptides a clinic can actually offer today, the launch stack, what it costs to do it yourself versus on a platform, and the day-one plan for when the FDA list finally moves.
After the Votes: Turning July's FDA Peptide Meeting Into a 2027 Roadmap
The FDA's advisory committee spent two days last week reviewing seven of the most-requested peptides in consumer health. Whatever your read on the individual votes, the strategic picture is now clearer than it has been in years: the review pathway is real, the timeline runs through rulemaking, and the operators who use the interval to build governance, demand, and infrastructure will own the category when the rules settle. Here is the after-meeting roadmap.
The Membership-Model Longevity Clinic: Labs, Peptides, Hormones, One Platform
A wave of longevity clinics launched this summer with the same architecture: an annual membership wrapping comprehensive labs, clinician review, and a protocol layer spanning hormones, peptides where compliant, and metabolic medications. The model works because it matches how longevity patients actually think, in systems and years rather than prescriptions and months. Here is the full blueprint, from diagnostic spine to renewal economics.
The Longevity Stack: Combining NAD+, Peptides, GLP-1, and Rapamycin in One DTC Program
Longevity patients rarely want a single compound. They want a stack. Combining NAD+, peptides, GLP-1, and rapamycin in one DTC program is a real opportunity, but only if intake, provider scope, sequencing, billing, and compliance are built for a multi-compound model instead of bolted together from separate funnels.
NAD+ Delivery Formats Compared: IV vs. Injection vs. Nasal Spray vs. Oral Precursors
NAD+ is the same molecule no matter how a patient takes it, but the delivery format changes everything about evidence, cost, adherence, compliance, and patient experience. This is how DTC telehealth teams should compare IV, subcutaneous injection, nasal spray, and oral precursors before building a NAD+ program.